


EVOLUTION OF eGFR



WHAT IT MEANS



Protect your kidneys



Healthy lifestyle, regular check-up



Monitor and control risk factors




Follow treatment and doctor's advice



Plan for renal replacement therapy

Lower eGFR over time means worsening kidney function.
Early detection and care can slow the decline! ❤️

eGFR and Use of OHA



Lower eGFR means choose OHA carefully!

OHA	eGFR (mL/min/1.73 m ²)				
	≥ 90	60–89	45–59	30–44	< 30
Metformin	✓ Safe	✓ Safe	⚠ Use with caution (Max 1000 mg/day)	✗ Avoid / Stop	✗ Contraindicated
Sulfonylureas (Glimepiride, Gliclazide)	✓ Safe	✓ Safe	⚠ Use lower dose	⚠ High risk hypoglycemia Use very low dose	✗ Avoid
DPP–4 inhibitors (Sitagliptin, Vildagliptin)	✓ Safe	✓ Safe	⚠ Reduce dose (Sitagliptin 50 mg)	⚠ Reduce dose (Sitagliptin 25 mg)	⚠ Use with caution (Sitagliptin 25 mg)
Linagliptin (DPP–4 inhibitor)	✓ Safe	✓ Safe	✓ No dose adjustment needed	✓ No dose adjustment needed	✓ Safe (no dose adjustment needed)
SGLT2 inhibitors (Dapagliflozin, Empagliflozin)	✓ Safe	✓ Safe (↑ kidney benefit)	⚠ May continue for kidney & CV benefit	⚠ Usually not effective (Glycemic benefit low)	✗ Avoid / Stop
Others (Acarbose, Pioglitazone)	Generally safe	Generally safe	Use with caution	Use with caution	Use with caution



ECNG
Meetings Without Cancellation

DATE
1/6/2026


TIME
9–10 PM

ZOOM MEETING
zoom

Right OHA choice + Regular eGFR monitoring = Better outcomes! ♥

- ✓ Check eGFR regularly
- ✓ Adjust OHA as eGFR falls
- ✓ Avoid nephrotoxic drugs
- ✓ Prevent AKI (dehydration, contrast, NSAIDs)

* Doses may vary based on local guidelines and individual patient factors.



Healthy kidneys,
Better life! ♥



ECNG
Meetings Without Cancellation

EVOLUTION OF ORAL HYPOGLYCAEMIC DRUGS

From the Past to Better Control

1950s–1960s
THE BEGINNING

SULFONYLUREAS
(1st Generation)

I stimulate
insulin secretion!




First oral agents to
treat type 2 diabetes

1970s–1980s
BETTER & SAFER

SULFONYLUREAS
(2nd Generation)

Stronger &
longer acting!



More potent,
improved efficacy

1990s
NEW MECHANISMS
EMERGE

BIGUANIDE

I reduce hepatic
glucose production
& improve sensitivity!



The foundation
still going strong!

2000s
BEYOND INSULIN
SECRETION

**NEW CLASSES
ARRIVE**

I improve
insulin
sensitivity!

I enhance
incretins!



New targets,
new possibilities

2010s
MORE OPTIONS,
MORE CONTROL

**SGLT2
INHIBITORS**


I help kidneys
remove glucose!



Benefits beyond
glycaemic control

2020s AND BEYOND
PERSONALIZED &
COMBINATION CARE

Different paths...
One goal – Better
outcomes!



**TARGET-BASED THERAPY
PATIENT-CENTRED CARE
BETTER OUTCOMES**

